Gottschalk J, Jautzke G, Märzheuser-Brands S, Cervos-Navarro J
Abteilung Pathologie, Allgemeines Krankenhaus Heidberg, Hamburg.
Zentralbl Pathol. 1993 Nov;139(4-5):343-9.
Occasionally variants of meningeal hemangiopericytomas (HPC) may be confused with primary and secondary tumours of the meninges by virtue of their features and patterns of growth. Until now, a specific immunohistochemical marker for HPC could not be identified. HPC are reported to express factor XIIIa (F XIIIa) in the cytoplasm of the tumour cells. In an effort to assess the diagnostic value of F XIIIa for meningeal HPC, we investigated 38 primary meningeal tumours (6 HPC, 28 meningiomas of various subtypes, 4 meningeal sarcomas) and 23 secondary meningeal tumors (8 metastatic carcinomas, 6 gliosarcomas, 9 anaplastic gliomas) with anti-F XIIIa antibody. All HPC revealed 5%-20% of F-XIIIa-positive neoplastic cells. Malignant fibrous histiocytomas and gliosarcomas with MFH-like structures also exhibited multiple F-XIIIa-positive cells. Most of the F-XIIIa-positive cells in meningiomas were identified as macrophages. Furthermore, there was a population of small dark cells of uncertain histogenesis. Cells with positive immunoreactivity for F-XIIIa in metastatic carcinomas and gliomas apparently were of macrophage lineage. Though, in some cases, it would have been difficult to distinguish reactive from neoplastic cells without simultaneous immunohistochemical investigation with antibodies for macrophages, cytokeratin, EMA and GFAP. Because of these uncertainties, wo believe that the potential of F XIIIa-antibody in obtaining precise differential diagnostic information is limited.
偶尔，脑膜血管外皮细胞瘤（HPC）的变种可能因其特征和生长模式而与原发性和继发性脑膜肿瘤相混淆。到目前为止，尚未发现HPC的特异性免疫组化标志物。据报道，HPC在肿瘤细胞的细胞质中表达因子ⅩⅢa（FⅩⅢa）。为了评估FⅩⅢa对脑膜HPC的诊断价值，我们用抗FⅩⅢa抗体研究了38例原发性脑膜肿瘤（6例HPC、28例不同亚型的脑膜瘤、4例脑膜肉瘤）和23例继发性脑膜肿瘤（8例转移性癌、6例胶质肉瘤、9例间变性胶质瘤）。所有HPC均显示5%-20%的肿瘤细胞FⅩⅢa阳性。具有MFH样结构的恶性纤维组织细胞瘤和胶质肉瘤也有多个FⅩⅢa阳性细胞。脑膜瘤中大多数FⅩⅢa阳性细胞被鉴定为巨噬细胞。此外，还有一群组织发生不明的小暗细胞。转移性癌和胶质瘤中FⅩⅢa免疫反应阳性的细胞显然属于巨噬细胞谱系。不过，在某些情况下，如果不同时用巨噬细胞、细胞角蛋白、EMA和GFAP抗体进行免疫组化研究，很难区分反应性细胞和肿瘤细胞。由于存在这些不确定性，我们认为FⅩⅢa抗体在获取精确鉴别诊断信息方面的潜力有限。
